Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 22;11(1):32.
doi: 10.3390/healthcare11010032.

Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials

Areeba Rashad  1 , Atta Rasool  2 , Muhammad Shaheryar  3 , Azza Sarfraz  4 , Zouina Sarfraz  1 , Karla Robles-Velasco  5 , Ivan Cherrez-Ojeda  5
Affiliations

Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials

Areeba Rashad et al. Healthcare (Basel). .

Abstract

Amyloid-β (Aβ) plaques and aggregated tau are two core mechanisms that contribute to the clinical deterioration of Alzheimer’s disease (AD). Recently, targeted-Aβ plaque reduction immunotherapies have been explored for their efficacy and safety as AD treatment. This systematic review critically reviews the latest evidence of Donanemab, a humanized antibody that targets the reduction in Aβ plaques, in AD patients. Comprehensive systematic search was conducted across PubMed/MEDLINE, CINAHL Plus, Web of Science, Cochrane, and Scopus. This study adhered to PRISMA Statement 2020 guidelines. Adult patients with Alzheimer’s disease being intervened with Donanemab compared to placebo or standard of care in the clinical trial setting were included. A total of 396 patients across four studies received either Donanemab or a placebo (228 and 168 participants, respectively). The Aβ-plaque reduction was found to be dependent upon baseline levels, such that lower baseline levels had complete amyloid clearance (<24.1 Centiloids). There was a slowing of overall tau levels accumulation as well as relatively reduced functional and cognitive decline noted on the Integrated Alzheimer’s Disease Rating Scale by 32% in the Donanemab arm. The safety of Donanemab was established with key adverse events related to Amyloid-Related Imaging Abnormalities (ARIA), ranging between 26.1 and 30.5% across the trials. There is preliminary support for delayed cognitive and functional decline with Donanemab among patients with mild-to-moderate AD. It remains unclear whether Donenameb extends therapeutic benefits that can modify and improve the clinical status of AD patients. Further trials can explore the interplay between Aβ-plaque reduction and toxic tau levels to derive meaningful clinical benefits in AD patients suffering from cognitive impairment.

Keywords: Alzheimer’s disease; cognition; donanemab; elderly care; plaque.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart depicting the study selection process.
Figure 2
Figure 2
Risk-of-bias assessment of RCTs using the ROB-2 tool. Traffic light plot of study-by-study bias assessment. Weighted summary plot of the overall type of bias encountered in all studies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McKeown A., Turner A., Angehrn Z., Gove D., Ly A., Nordon C., Nelson M., Tochel C., Mittelstadt B., Keenan A. Health Outcome Prioritization in Alzheimer’s Disease: Understanding the Ethical Landscape. J. Alzheimers Dis. 2020;77:339–353. doi: 10.3233/JAD-191300. - DOI - PMC - PubMed
    1. Nandi A., Counts N., Chen S., Seligman B., Tortorice D., Vigo D., Bloom D.E. Global and regional projections of the economic burden of Alzheimer’s disease and related dementias from 2019 to 2050: A value of statistical life approach. EClinicalMedicine. 2022;51:101580. doi: 10.1016/j.eclinm.2022.101580. - DOI - PMC - PubMed
    1. Schwarzinger M., Dufouil C. Forecasting the prevalence of dementia. Lancet Public Health. 2022;7:e94–e95. doi: 10.1016/S2468-2667(21)00277-2. - DOI - PubMed
    1. Yiannopoulou K.G., Anastasiou A.I., Zachariou V., Pelidou S.-H. Reasons for failed trials of disease-modifying treatments for Alzheimer disease and their contribution in recent research. Biomedicines. 2019;7:97. doi: 10.3390/biomedicines7040097. - DOI - PMC - PubMed
    1. Panza F., Solfrizzi V., Frisardi V., Capurso C., D’Introno A., Colacicco A.M., Vendemiale G., Capurso A., Imbimbo B.P. Disease-modifying approach to the treatment of Alzheimer’s disease. Drugs Aging. 2009;26:537–555. doi: 10.2165/11315770-000000000-00000. - DOI - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources